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Rheumatoid arthritis is a chronic, inflammatory disorder
that affects primarily the joints and causes significant dis-
ability to affected individuals. Although the recent years
have brought exciting new information to researchers and
clinicians alike, the treatment of the disease still consti-
tutes a major challenge. Most patients require a combina-
tion of different medications, including nonsteroidal
anti-inflammatory drugs, early and aggressive application
of disease modifying anti-rheumatics, and steroids. Using
such regimens, slowing of disease progression can be
observed in some patients, but frequently the treatment
fails to achieve satisfactory results. Specifically, the pro-
gressive destruction of articular cartilage and bone is
barely influenced at all by most of the approaches that we
use routinely today. This is of particular concern because
the joint destruction not only constitutes a most promi-
nent feature of disease, but also determines its outcome in
the majority of patients.
Therefore, the development of new ‘biological’ agents
that interfere specifically with cytokine-mediated inflam-
matory pathways and activation of synovial cells has been
followed as a novel therapeutic approach with great inter-
est. Indeed, clinical studies that used monoclonal antibod-
ies against tumour necrosis factor (TNF)-a, as well as
different TNF receptor fusion proteins, have provided
convincing results [1,2]. It was shown that the administra-
tion of such proteins effectively influences the clinical fea-
tures of disease. Growing experience in using these agents
has also unveiled some limitations, however. Not only
have there been concerns about a potential immunogene-
ity and the development of autoantibodies, but also, and
more importantly, the systemic inhibition of TNF-a over
a long time may bear some as yet unknown risks.
In the search for alternatives, gene transfer has become an
interesting novel approach for interfering with key
processes in rheumatoid arthritis. Although gene transfer
was developed originally to treat inherited diseases by cor-
recting the underlying genetic abnormality, it has been
understood that gene transfer also provides new opportu-
nities for treating acquired disorders. In the field of
rheumatoid arthritis, Evans has been the pioneer.
Together with his colleagues, he was the first to demon-
strate that gene transfer to synovial cells is a feasible tool
for altering the course of disease in animal models of
arthritis. His review article in this issue of Arthritis Research
summarizes this experience [3]. Clearly, delivering the
genes that encode therapeutic proteins rather than admin-
istering these proteins directly appears attractive for
several reasons. In particular, gene transfer has been sug-
gested to overcome major disadvantages of conventional
pharmacology, and has been associated with a selective
and highly specific targeting of disease mechanisms at the
molecular level. Not surprisingly, expectations for gene
therapy approaches have been high among both scientists
and clinicians. Visible progress has been made mainly on
the experimental, rather than clinical side so far. Although
researchers have been using gene transfer widely to study
the molecular mechanisms of disease and have made it a
standard tool for investigating functional relationships in
cells of the rheumatoid synovium, the therapeutic impact
that can be expected from gene therapy is still a matter of
debate. Specifically, the question of what molecules or
pathways should be targeted to inhibit the joint destruc-
tion in rheumatoid arthritis has been controversial.
It is well established that inflammation constitutes a major
feature of rheumatoid arthritis, and inflammatoryArthritis Research    Vol 1 No 1 Pap et al
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cytokines such as interleukin-1 and TNF-a are produced
at high levels in the rheumatoid synovium. By activating
receptor-induced intracellular signalling pathways, these
cytokines trigger several disease-related pathways and can
induce mediators of disease such as matrix metallopro-
teinases (MMPs) [4]. This understanding, together with
the promising data from novel anticytokine therapies,
have made proinflammatory cytokines a major target also
for gene therapy [1,2]. As outlined by Evans et al in this
issue of Arthritis Research [3], there has been considerable
progress in delivering antagonists of proinflammatory
cytokines, as well as of anti-inflammatory mediators, to
the synovium of different animals, and it has been shown
that targeting inflammatory pathways substantially
reduces the severity of antigen-induced arthritis. In addi-
tion, it was demonstrated in the severe combined immun-
odeficiency (SCID) mouse model of rheumatoid arthritis
that overexpression of the interleukin-1 receptor antago-
nist (IL-1Ra) in human rheumatoid arthritis synovial
fibroblasts (RA-SFs) has chondroprotective effects [5]. In
that study, RA-SFs were transduced with the gene for IL-
1Ra or a control (LacZ) gene and coimplanted with normal
human cartilage under the renal capsule of SCID mice.
Because SCID mice lack a functional immune system,
they do not reject the implants and permit study of the
invasive behaviour of genetically modified and control
RA-SFs. Interestingly, overexpression of the IL-1Ra in
RA-SFs, did not reduce significantly the invasiveness of
these cells into the cartilage. Instead, the chondroprotec-
tive effect was due to an inhibition of the perichondrocytic
matrix degradation. Conversely, gene transfer of the inter-
leukin-10 gene significantly reduced the invasion of RA-
SFs into the coimplanted cartilage, but had little effect on
the perichondrocytic degradation [6]. It has to be noted,
however, that in spite of their indisputable value for
research, animal models do not reflect the complete reality
of human rheumatoid arthritis. This is demonstrated by
recent findings indicating that the combination treatment
with anti-TNF-a antibodies and methotrexate clearly
retard the progression of radiological changes in rheuma-
toid arthritis (Maini RN, personal communication).
Inhibition of a single proinflammatory cytokine may not
be sufficient to inhibit inflammatory pathways in rheuma-
toid arthritis in the long run. Rather, it appears necessary
that the genes for two or even more antagonists of proin-
flammatory cytokines need to be delivered at the same
time using appropriate vectors and expression cassettes.
Notably, the simultaneous inhibition of several proinflam-
matory cytokines may constitute an advantage of gene
transfer as compared with the delivery of the individual
recombinant proteins. Based on this understanding, Evans
et al [7] initiated the first clinical trial of gene transfer for
human rheumatoid arthritis. In that study, ex vivo gene
transfer with a retroviral vector carrying the IL-1Ra gene
was used to transduce synovial fibroblasts from nine
patients before a scheduled joint replacement. It needs to
be stressed that this trial was not designed to assess the
clinical efficacy of gene transfer with the IL-1Ra gene, but
to demonstrate the feasibility of this approach.
When addressing rheumatoid joint destruction, however,
we have to remember that inflammation reflects only one
aspect of the pathogenesis of rheumatoid arthritis. Not
only have clinical data provided evidence that the patho-
logical mechanisms of inflammation and articular damage
may differ [8], but experiments in the SCID mouse model
of rheumatoid arthritis, as well as in vitro data, have
demonstrated that the aggressive potential of RA-SFs is
maintained in the absence of inflammatory cells [9]. It has
been established by numerous studies that the activation
of synovial fibroblasts in the lining layer of the rheumatoid
synovium plays a pivotal role in the progressive degrada-
tion of cartilage. When compared with normal synovial
fibroblasts, these activated RA-SFs exhibit a different
morphology and significant alterations in their behaviour.
Molecular changes in RA-SFs comprise the upregulation
of several proto-oncogenes as well as the downregulation
and functional inactivation of potentially protective
(tumour suppressor) genes. Firestein et al [10] have
demonstrated convincingly that somatic mutations in the
p53 tumour suppressor occur in a number of patients with
rheumatoid arthritis, with the predicted amino acid substi-
tutions being similar to those observed in tumors.
Although such mutations appear not to be present in some
other populations of rheumatoid arthritis patients [11], it
has been established that nonfunctional p53 may account
for altered signalling in RA-SFs. As reported in the next
issue of Arthritis Research [12], aggressive RA-SFs also lack
the expression of the tumour suppressor PTEN, which
exhibits tyrosine phosphatase activity as well as homology
to the cytoskeletal proteins tensin and auxilin [13]. Inter-
estingly, mutations in PTEN resulting in a nonfunctional
molecule have also been described in several human
cancers and are associated with the invasive and metasta-
tic properties of malignancies [14].
It is now established that the activation of synovial fibrob-
lasts in the rheumatoid arthritis synovium alters the regu-
lation of various genes and ultimately results in the
progressive destruction of cartilage in rheumatoid arthritis.
In this context, three distinct processes have been shown
to contribute to the aggressive behaviour of RA-SF: upreg-
ulation of adhesion molecules that mediate the attach-
ment of RA-SFs to cartilage; expression of matrix
degrading enzymes such as MMPs and cathepsins; and
prolonged survival of RA-SF because of inhibited apop-
totic pathways. These changes are highly complex, and
one has to be aware that our understanding of signalling
pathways in RA-SFs, and particularly the role of individual
molecules, is still rather fragmented. Despite major
advances in our understanding of specific pathways, it has7
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become evident that activation of synovial cells in
rheumatoid arthritis involves the whole complexity of cel-
lular signalling, and not just two or three paths. Therefore,
targeting rheumatoid joint destruction requires several
distinct approaches to be followed (Fig. 1). Apart from
interrupting the effect of macrophage-derived proinflam-
matory cytokines that stimulate the RA-SF, the specific
properties of these cells need to be targeted.
Among the different molecules that have been implicated
in the activation of RA-SF, upregulation of the transcrip-
tion factors AP-1 and NF-kB have become of particular
interest. The AP-1 transcription factor consists of the c-
Fos and c-Jun elements, and appears to constitute a key
element in the signalling pathways that ultimately lead to
the degradation of cartilage and bone in rheumatoid arthri-
tis. Not only are c-Fos and c-Jun overexpressed in the
rheumatoid arthritis synovium [15–17], but the promoters
of several MMP genes contain consensus binding sites for
the transcription factor AP-1. In addition, AP-1 sites have
been shown to be involved in tissue-specific expression of
MMPs [18]. Therefore, interfering with pathways that
upregulate the AP-1 complex may inhibit the rheumatoid
joint destruction [19]. In this context, the delivery and
overexpression of genes that encode nonfunctional sig-
nalling molecules (dominant-negative mutants) not only
permits investigation of the specific role of such mole-
cules, but also permits assessment of the therapeutic
potential of their inhibition.
Using this technique, we recently investigated the effect
of retroviral gene transfer with dominant negative mutants
of Raf-1 on the invasiveness of RA-SFs, as well as on the
expression of AP-1-related proteins and MMPs [20]. It was
demonstrated, in RA-SFs, that Raf-1 is involved in sig-
nalling cascades that upregulate disease-relevant MMPs
though the activation of c-Jun. Despite an effect on the
expression of c-Jun, as well as on the expression of MMP-
1 and MMP-13, however, invasiveness of RA-SFs was not
inhibited completely in the SCID mouse model. Also, no
complete inhibition of the MMP production was
observed. These data demonstrate the complexity of sig-
nalling pathways in RA-SFs and suggest that Raf-inde-
pendent pathways are involved critically in the activation
of these cells. Moreover, these data confirm other observa-
tions suggesting that AP-1 sites do not regulate the tran-
scription of MMPs alone. Rather, there are essential
interactions with other cis-acting sequences in the promot-
ers and with transcription factors that bind to these
sequences [18].
The transcription factor nuclear factor-kB (NF-kB) is also
highly activated in the synovial membrane of rheumatoid
arthritis patients, particularly in RA-SFs [21]. NF-kB can
be induced through proinflammatory cytokines, but, con-
versely, NF-kB activation induces the transcription of
such cytokines, as well as of adhesion molecules. There-
fore, the activation of NF-kB in synovial cells appears to
be an important factor in the perpetuation of rheumatoid
arthritis [22] and to play a major role in synovial inflamma-
tion. A study by Makarov et al [23] most recently demon-
strated that inhibition of NF-kB through gene transfer
with IkB may constitute a feasible tool for inhibiting the
inflammatory response.
Interfering with the attachment of RA-SFs to the cartilage
constitutes another major target for gene transfer
approaches to alter the specific pathology of RA-SFs. Inte-
grins have been implicated most frequently in the attach-
ment of RA-SFs to cartilage, and several studies have
demonstrated the expression of b1-integrins such as very
late antigen (VLA)-3, VLA-4 and VLA-5 on synovial
Figure 1
Targeting joint destruction in rheumatoid arthritis
requires the inhibition of several pathways. Apart
from interrupting the effect of macrophage-
derived proinflammatory cytokines that stimulate
the rheumatoid arthritis synovial fibroblasts (RA-
SFs), the specific properties of these cells need
to be targeted. This comprises the inhibition of
cellular activation of RA-SFs, their attachment to
the cartilage, the invasion into the cartilage
through the release of matrix-degrading enzymes,
altered apoptosis and angiogenesis.fibroblasts [24]. In addition, anti-b1 integrin antibodies
inhibit, at least in part, the binding of synovial fibroblasts
to extracellular matrix [25]. However, integrins have
become of interest for rheumatoid arthritis not only
because of their function as receptor molecules, but also
because of their interaction with several signalling path-
ways and cellular proto-oncogenes [26]. Specifically, the
expression of early cell cycle genes such as c-fos and c-myc
is also stimulated by integrin-mediated cell adhesion, and
gene expression driven by the fos promoter shows strong
synergistic activation by integrin-mediated adhesion
[27,28]. Therefore, inhibiting the expression of integrins
directly in RA-SFs through gene transfer appears much
more promising than the delivery of antibodies to block
integrins on the cell surface.
Apart from the integrins, vascular cell adhesion molecule
(VCAM)-1 has been characterized as an important adhe-
sion molecule associated with the activated phenotype of
RA-SF. Several studies [29–31] have revealed high
expression of VCAM-1 in RA-SFs, particularly in the
lining layer. Although the specific role of VCAM-1 in the
attachment of these cells to the cartilage needs to be
established, a recent study [32] demonstrated that soluble
VCAM-1 exhibits chemotactic activity to T cells that
express high affinity VLA-4. Interestingly, the chemotac-
tic activity of soluble VCAM-1 is inhibited in the presence
of anti-VCAM-1 and anti-VLA-4 [32], suggesting that
VCAM-1 produced by RA-SFs contributes to the develop-
ment of the synovial inflammation by attracting T cells to
the joint. As demonstrated by other studies VCAM-1 may
also contribute to T-cell anergy [33] and the induction of
angiogenesis [34]. From these studies it can be anticipated
that inhibiting the expression of VCAM-1 in RA-SFs may
lead to several beneficial effects in rheumatoid arthritis.
Angiogenesis, a very early feature of rheumatoid arthritis
[35], appears to be a target for gene transfer by itself,
however. By inhibiting angiogenesis, the influx of inflam-
matory cells to the joint might be reduced significantly
[34].
Another promising approach that is aimed at modulating
the terminal phase of MMP and cathepsin upregulation by
cleaving the messenger RNA for these enzymes. This can
be achieved by the delivery and expression of ribozymes
to RA-SFs. Ribozymes are RNA molecules that are able to
cleave RNA in a site-specific manner. Such ribozymes can
be used to destroy messages inside cells. RA-SFs in which
ribozymes capable of cleaving collagenase are expressed
will therefore produce no or only limited amounts of this
enzyme. The usefulness of this mode to reduce the inva-
siveness of RA-SFs is currently being evaluated [36].
Recent data have also provided evidence for changes of
apoptotic pathways in the rheumatoid arthritis synovium.
Specifically, it has been demonstrated that apoptosis is a
rare event among RA-SFs. This applies predominantly to
the lining layer, and the changes appear closely linked to
the activated phenotype of RA-SF. As for possible mecha-
nisms that may extend the life-span of lining layer RA-
SFs, we have demonstrated most recently [37] that the
novel antiapoptotic molecule sentrin is strongly expressed
in rheumatoid arthritis synovium. Sentrin has been shown
to interact with the signal competent forms of Fas/Apo-1
and TNF receptor-1, and thereby to protect cells against
anti-Fas and TNF-induced cell death. Interestingly,
sentrin is found mainly in rheumatoid arthritis synovial
lining cells, whereas normal synovium cells express only
very little sentrin messenger RNA [37]. Therefore, it is
suggested that inhibiting the expression of sentrin in RA-
SFs may reduce their invasiveness through interfering
with altered apoptosis and normalizing the life-span of
these cell. Because somatic mutations in p53 tumour sup-
pressor gene in RA-SF and NF-kB-mediated pathways
also contribute to the reduced apoptosis of RA-SFs, gene
transfer approaches targeting these molecules may also
affect the life-span of RA-SFs beneficially.
The clinical application of these approaches faces some
major problems, however. As emphasized in a recent
article by Jorgensen and Gay [36], premature application
of gene therapy without appropriate delivery techniques
and protocols may do more harm than good. Clearly, clini-
cal trials that are aimed at demonstrating the efficacy of
gene therapy approaches in rheumatoid arthritis have to
use its fundamental advantages rather than just providing
another vehicle. In this context, the design and utilization
of vectors that ensure safe and effective delivery of poten-
tial transgenes, as well as their long-lasting expression,
needs further research. Evans et al have addressed this
problem extensively in this issue of Arthritis Research [3],
and it has been suggested that the most appropriate strat-
egy is the direct intra-articular injection of appropriate
vectors. Indeed, the development of vectors for in vivo
gene transfer has been favoured, not only because of their
ease of use, but also and more importantly because of cost
effectiveness. Today, most approaches focus on the use of
vectors that at least bear the potential for in vivo use, and
several studies have demonstrated that synovial cells can
be transduced effectively by the intra-articular injection of
different (viral) vectors. As for the aforementioned targets,
there is yet another argument for the in vivo approach.
Transducing a limited number of isolated cells ex vivo and
reinjecting them into the joint may be sufficient to ensure
the continuous local production of secreted proteins;
however, altering intracellular signalling pathways or gene
expressions will not be effective unless the majority of
RA-SFs is targeted. On the other hand, one has to bear in
mind that genetic modifications to signalling cascades may
result in severe side effects when cells other than the
pathological ones are affected. Therefore, it is anticipated
that in vivo gene transfer for rheumatoid arthritis that is
Arthritis Research    Vol 1 No 1 Pap et al
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siveness of RA-SFs will not be successful without cell-
specific delivery of the transgene.
In conclusion, there is a great potential for gene therapy
approaches in rheumatoid arthritis, not only for the site
specific and long-lasting delivery of therapeutic proteins,
but also for the specific targeting of disease processes that
are characteristic and unique for rheumatoid arthritis.
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